Kwang Nho

Peg-Bovine Hemoglobin: Safety en a Canine Dehydrated Hypovolemic-Hemorrhagic Shock Model

An initial evaluation of PEG-bHb was performed using a modified hypovolemic shock model. PEG-bHb had a substantially longer intravascular half-life than native Hb and no measurable hemoglobinuria was observed in the canine. PEG-bHb allowed successful resuscitation with an oxygen carrying capacity of 14-22% over that of lactated Ringers solution.

Peg-Hemoglobin:an Efficient Oxygen-Delivery System in the Rat Exchange Transfusion and Hypovolemic Shock Models

Polyethylene glycol-hemoglobin (PEG-Hb is a purified bovine hemoglobin molecule modified by polyethylene glycol. Oxygen delivery to the tissue, in rat exchange transfusion and hypovolemic shock models, was studied to determine whether the oxygen-carrying capacity of PEG-Hb is as efficient as red blood cells.

Production of Peg-Modified Bovine Hemoglobin: Economics and Feasibility

Bovine hemoglobin has many advantages as a blood substitute: a) its ready availability; b) its low cost; c) its oxygen carrying capacity; and d) the ease with which it can be modified with polyethylene glycol (PEG) to improve its pharmacokinetic profile. This study investigates the potential of PEG-modified bovine hemoglobin as a cost-effective blood substitute.

PEG-Modified Hemoglobin as an Oxygen Carrier

A need is strongly recognized for a safe red cell substitute that can carry oxygen to the hypoxic tissues of an anemic body. Banked blood is in short supply because of mounting fears of donors and limited storage life. A safe, stable, oxygen carrier would eliminate many problems such as cross-matching of blood types, danger of virus infections, short shelf life, and availability. Not only could this be used as an oxygen-carrying plasma expander for trauma victims and patients in surgery, such as cardiac bypass and angioplasty, this product could also be used as a perfusate for the preservation of isolated organs for transplantation. Cold storage is the popular choice for preservation at present, but there is an increasing demand for a safe organ perfusate that would promote the use of perfusion preservation to obtain a longer period of preservation.

Pharmacokinetics of 125I-radiolabelled PEG-hemoglobin SB1

PEG-hemoglobin SB1 (SB1) is a polyethylene glycol (PEG)-modified hemoglobin-based oxygen carrier, intended for use as resuscitation fluid for brain stroke and as a blood substitute. An intravenous pharmacokinetics (PK) studies with SB1 was investigated in male albino Sprague-Dawley (SD) rats and male beagle dogs at doses of 5 and 12.5 ml/kg for rats and 10 ml/kg for dogs. Total hemoglobin in plasma and whole blood was determined by gamma scintillation counter–detecting 125I-radiolabelled SB1. In the 5 ml/kg rats (n = 9), the Cmax, t1/2, AUCt and Tmax were 9.055 mg equivalents/ml, 9.6 hr, 79.6 mg equivalents.hr/ml and 0.20 hr in the plasma and 4.954 mg equivalents/ml, 9.7 hr, 37.6 mg equivalents.hr/ml and 0.11 hr in the whole blood, respectively. Those parameters in the 12.5 ml/Kg of rats (n = 9) were 19.00 mg equivalents/ml, 10.6 hr, 223.5 mg equivalents.hr/ml and 0.33 hr in the plasma and 10.58 mg equivalents/ml, 16.1 hr, 99.0 mg equivalents.hr/ml and 0.33 hr in the whole blood, respectively. An increase in the dose level from 5 to 12.5 ml/kg resulted in the increase in both Cmax and AUC24, and the increases in these parameters appeared to be in proportion to the dose increment. Thus, following the 2.5-fold increase in administered dose, Cmax was increased by a factor of 2.1 in both plasma and whole blood, while AUC24 was increased by a factor of 2.8 for plasma and 2.6 for whole blood. In the dogs receiving 10 ml/kg (n = 3), the Cmax, t1/2, AUC168 and Tmax were 12.70 mg equivalents/ml, 47.2 hr, 425.7 mg equivalents.hr/ml and 0.083 hr in the plasma and 8.372 mg equivalents/ml, 50.3 hr, 241.3 mg equivalents.hr/ml and 1.003 hr in the whole blood, respectively. The present work provides an insight into the pharmacological behavior of a PEG-modified hemoglobin.

Normal oxygen tension restored in the ischemic rat liver model by PEG-hemoglobin.

Cell damage initiated during ischemia, as a result of oxygen depletion, continues during reperfusion, and recovery is dependent on the length of the ischemic period. This study investigates the effect of polyethylene glycol-modified hemoglobin (PEG-Hb) on recovery of tissue oxygen tension after induced ischemia.